Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/867"
| Predicate | Value (sorted: none) |
|---|
| rdf:type |
|
| rdf:type |
|
| rdfs:label |
|
| ?:Evidence_type |
|
| ?:Evidence_enzyme_system |
|
| dc:creator |
|
| dc:date |
|
| ?:content |
"Route of administration: oral
polymorphic enzyme: NO
study duration: 2 days ketoconazole pretreatment
population: 8 male, 13 female
ages:23-55
description:
Plasma concentrations of midazolam, 1'OH-midazolam and 4'OH-midazolam were measured after the oral administration of 7.5 mg and 75 micro g midazolam in 13 healthy subjects without medication, in four subjects pretreated for 2 days with ketoconazole (200 mg b.i.d.), a CYP3A inhibitor, and in four subjects pretreated for 4 days with rifampicin (450 mg q.d.), a CYP3A inducer. RESULTS: After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively. No side effects were reported by the subjects taking this low dose of midazolam. Good correlations were observed between the 30-min total 1'OH-midazolam/midazolam ratio and midazolam clearance in the group without co-medication (r(2)=0.64, P<0.001) and in the three groups taken together (r(2)=0.91, P<0.0001)."
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ketoconazole_does_not_inhibit_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1962 }
Context graph
